Basiliximab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Basiliximab. Educational only — not medical advice.
Labeled uses
Simulect® (basiliximab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine, USP (MODIFIED), and corticosteroids. The efficacy of Simulect for the prophylaxis of acute rejection in recipients of other solid organ allografts has not been demonstrated.
Source: FDA labeling via NIH DailyMed (set 1af01887…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.